Clinical Trial

Amping up With PemJAK

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Trial Details
NCT Number NCT07283822
Lead Sponsor Seda S. Tolu
Collaborators: Incyte Corporation
Conditions Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent, Gray Zone Lymphoma, Peripheral T-cell Lymphoma, Cutaneous T-Cell Lymphomas, Primary Mediastinal B Cell Lymphoma
Enrollment 53 participants
Start Date 2025-12-03
Primary Completion 2028-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-16